Paper TrailKOREA
Why Korean and U.S. stocks moved, checked against filings

Insmed Up 21% With No Filing, Anthropic Closes Debut at $97.17: Nov 19 Movers

While the S&P 500 fell 2.02%, Insmed rose 20.6% on a report that Sanofi is weighing a takeover, with no company filing behind it. Anthropic closed its Nasdaq debut at $97.17, up 17.07%, well below its intraday high.

Insmed Up 21% With No Filing, Anthropic Closes Debut at $97.17: Nov 19 Movers

Seoul — A record of verified facts, not a stock recommendation. Figures as of 07:03 KST on Nov 20, 2026.

stock exchange

U.S. stocks fell on Nov 19: the S&P 500 lost 2.02% to 7,175.83, the Nasdaq Composite lost 2.25% to 23,879.20, and the Russell 2000 (the small-cap index) lost 2.18% to 2,655.11. Three stocks still closed up 10% or more. One reason is confirmed by SEC filings (Anthropic's IPO paperwork). The other two, Insmed and TELUS, rose on news reports, with no company filing confirming the story.

At a glance

Stock Why it rose Nature of the catalyst Basis Heat What to check next
Insmed (INSM) +20.6% Report that Sanofi is weighing a takeover Expectation Reports only 0/4 Whether the company confirms in an 8-K
Anthropic (ANT) +17.1% First day of Nasdaq trading, well off the intraday high Expectation Filings confirmed (IPO documents) Not yet measurable Lock-up expiry date, day-two close
TELUS (TU) +13.4% Quebecor bid, then a report of talks with BCE Expectation Reports only 0/4 Whether the company confirms talks

Insmed: up 20.6% on a Sanofi takeover report, with no company filing

Insmed (INSM) rose 20.58% to $144.46 on reports that Sanofi (SNY) is weighing a takeover. BigGo Finance ran the headline 'Sanofi Weighs Takeover of Insmed', and Benzinga, TIKR.com and Proactive carried the same story, putting the intraday jump near 18%. But Insmed filed nothing with the SEC in the past 7 days, so no company document confirms a bid or talks. For now the report is all there is.

That makes this an expectation-driven move. Seeking Alpha said an analyst thinks Insmed could be worth $170 to $210 a share in a takeover. That is the analyst's scenario, not an offer, though it would be roughly 18% to 45% above the close. The stock had already climbed about 49% from its Oct 28 close of $96.98, including a 15.06% jump on Oct 29 whose cause is not in the coverage we reviewed. Market value is about $31.7 billion, and dollar volume was about $2.08 billion.

On heat, signals are 0 of 4 (label: normal). RSI is 75.6, the price is 28.2% above its 20-day average, volume is 3.9 times the 20-day average, and the 5-day gain is 22.4%. The stock sits at 44% of its 52-week range, 31.7% below the 52-week high and 17.8% above the 200-day line. It passes 1 of 6 fundamentals checks: unprofitable with negative free cash flow, but revenue grew 268.4%. This is a record of the numbers, not a buy or sell signal.

To judge whether the move holds, watch whether Insmed or Sanofi confirms the review in an 8-K or press release, or denies it. Also watch whether the next session's dollar volume stays near today's $2.08 billion.

Anthropic: up 17% on debut day, but 15% below its intraday high

Anthropic recent price and volume

Anthropic (ANT) closed its first day on Nasdaq at $97.17, up 17.07% from the reference price, which works out to about $83 when backed out from the close and the percentage move. As a debut there is no earlier price to compare, and the move reflects enthusiasm for the listing itself, on a day the S&P 500 fell more than 2%. Eurasia Business News reported the stock opened at $111.50 after a record $81.3 billion offering. Beinsure said it was up 34% at one point, and Startup Fortune reported it fell 15% from its intraday high. The $97.17 close is about 12.9% below the opening price.

The SEC record shows the listing steps. On Nov 19 the company filed the final prospectus (424B4), a pricing FWP and two S-8 forms (employee equity plans). On Nov 18 came an EFFECT notice and three Form 3 filings (initial insider holding reports). All are IPO paperwork, and none is a separate piece of good news explaining today's price. Market value at the close is about $1.27 trillion and dollar volume about $82.8 billion. Revenue grew 1,126.9% but the company is unprofitable, passing 1 of 4 fundamentals checks. Because it is the first day, 20-day-average heat measures cannot be calculated yet. Coinpaper reported that Micron's (MU) $1 billion investment gained $343 million in value, a figure based on the 34% intraday surge.

To judge what comes next, look up the lock-up expiry date in the 424B4 (the period that bars existing holders from selling after listing). Also see whether the day-two close stays above the roughly $83 reference price; the first-day close is more than $14 above it.

TELUS: up 13% on Quebecor's bid and a report of BCE talks

TELUS (TU) rose 13.35% to $10.78 on a report of talks with BCE. Moomoo's headline reads 'Telus Shares Jump on Report of BCE Talks After Quebecor's Unsolicited Bid'. Rich Picks Daily said Quebecor proposed a combination valued at $19.45 a share, using the headline's own notation (it may be Canadian dollars). Yahoo! Finance Canada reported that Quebecor criticized Bell-Telus merger prospects while analysts called it a 'natural' fit, and National Bank Financial upgraded TELUS to Outperform the same day.

The only filing in the past 7 days is a 6-K dated Nov 16, three days before the report, so it does not confirm the BCE talks. The stock also rose 12.19% on Nov 16, gained 16.4% over two days (through Nov 18) and 26.5% over five. The catalyst is expectation: the bid and the talks are at the report stage, with no company confirmation. Revenue fell 0.9% year over year.

Heat signals are 0 of 4 (normal). RSI is 70.6, the price is 19.5% above its 20-day average, and volume is 2.8 times the 20-day average. It sits at 46% of its 52-week range, 24.7% below the 52-week high and 2.1% below the 200-day line, and passes 1 of 6 fundamentals checks (positive free cash flow).

To judge whether it holds, watch whether TELUS or BCE publicly confirms talks or says so in a 6-K, and whether TELUS's board responds to Quebecor's proposal.

FAQ

Why did they rise? Insmed on a report that Sanofi is weighing a takeover, Anthropic on its Nasdaq debut, TELUS on Quebecor's bid and a report of BCE talks.

What is the filing behind it? For Anthropic: the 424B4, FWP and S-8s filed Nov 19, plus the EFFECT notice and Form 3s filed Nov 18. Insmed has no filing in the past 7 days. TELUS has one 6-K, dated Nov 16, which does not confirm the talks.

What is the next date to watch? Anthropic's lock-up expiry is in its 424B4. For Insmed and TELUS, watch for an official confirmation (8-K, 6-K or press release).

Stocks we covered earlier, and what happened next

We compared the close on the article date with the Nov 19 close. The S&P 500 fell 2.02% that day.

Stock Article date Verdict then Close then Close Nov 19 Change
SELLAS Life Sciences (SLS) 11/18 Filing 19.15 14.86 -22.4%
BILL Holdings (BILL) 11/18 Reports 64.88 64.08 -1.2%
AECOM (ACM) 11/18 Earnings 80.53 80.31 -0.3%
CG Oncology, Inc. (CGON) 11/17 Filing 84.78 81.90 -3.4%
TELUS Corporation (TU) 11/17 Reports 9.57 10.78 +12.6%
Molina Healthcare, Inc. (MOH) 11/17 Reports 233.09 203.34 -12.8%
Modine Manufacturing (MOD) 11/14 Reports 135.66 134.56 -0.8%
Liftoff Mobile (LFTO) 11/14 Earnings 24.44 23.66 -3.2%

The four stocks tagged 'reports' split: TELUS +12.6%, BILL Holdings -1.2%, Modine -0.8%, Molina -12.8%. TELUS rose further on fresh reports. SELLAS, tagged 'filing', fell 22.4%, the most of the group. The two earnings-driven names, AECOM and Liftoff, moved -0.3% and -3.2%, less than the index drop.

FAQ

Why did Insmed Incorporated stock go up?

Report that Sanofi is weighing a takeover. Evidence: Reports only. What to check next: 0/4.

Why did Anthropic stock go up?

First day of Nasdaq trading, well off the intraday high. Evidence: Filings confirmed (IPO documents). What to check next: Not yet measurable.

Why did TELUS Corporation stock go up?

Quebecor bid, then a report of talks with BCE. Evidence: Reports only. What to check next: 0/4.

← Latest · Daily movers archive